The Solid Tumor Monitoring Profile (Liquid Biopsy) test uses next generation sequencing (NGS) performed on cell-free DNA (cfDNA) to identify molecular abnormalities in 275 genes implicated in solid tumors.
The Solid Tumor Monitoring Profile (Liquid Biopsy) is recommended only for monitoring patients after establishing the molecular abnormalities using a baseline tissue sample. It can be used for detecting minimal residual disease or the development of specific resistant mutations related to therapy (e.g. EGFR T790M mutation). We will analyze a tissue diagnostic sample, determine what genes are mutated in that baseline sample, then test the cfDNA for the specific mutations detected in the baseline sample.
Baseline tissue sample analysis is essential for proper molecular profiling of cancers. Tissue samples allow for the analysis of the RNA in addition to the DNA. RNA provides incredibly important information on expression pattern, overexpression, fusion genes, alternative splicing and mutations. We recommend tissue biopsy samples not only to establish baseline for monitoring, but for thorough evaluation including possible translocations that may involve ALK, ROS1, RET, NTRK, FGFR, etc. RNA testing allows for evaluation of the microenvironment (immune response, PD-L1, PD-L2, PD-1, CD8 cell, etc.). RNA analysis can also determine the MET exon 14 skipping and various alternative splicing and amplification of HER2, MET and EGFR. RNA information would be missing if the initial evaluation is performed by liquid biopsy alone.
Turn Around Time: 5-7 days
How to complete the Genomic Testing Cooperative requisition form.
Keep in mind that we do not accept blood samples directly from individuals. Talk with your M.D. to fill out the form for you.